{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:23:42Z","timestamp":1789503822013,"version":"build-2803163510"},"reference-count":78,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009425","name":"Landsteiner Foundation for Blood Transfusion Research","doi-asserted-by":"publisher","award":["1451"],"award-info":[{"award-number":["1451"]}],"id":[{"id":"10.13039\/100009425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jtha.2024.04.022","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T22:05:48Z","timestamp":1715205948000},"page":"2211-2226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors"],"prefix":"10.1016","volume":"22","author":[{"given":"Mark","family":"Schreuder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Jourdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejvid","family":"Veizaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"David A.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Lei","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Poenou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F.H.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Stepanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman M.","family":"Hackeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Gaussem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter H.","family":"Reitsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan P.","family":"Geerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Siguret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mettine H.A.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.04.022_bib1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2024.04.022_bib2","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib3","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"Pinto","year":"2007","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib4","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"DU-176b, a potent and orally active factor Xa inhibitor: in\u00a0vitro and in\u00a0vivo pharmacological profiles","volume":"6","author":"Furugohri","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib5","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bmcl.2009.02.111","article-title":"Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitor","volume":"19","author":"Zhang","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jtha.2024.04.022_bib6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure-based design of novel potent nonpeptide thrombin inhibitors","volume":"45","author":"Hauel","year":"2002","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1160\/TH16-10-0807","article-title":"New developments in anticoagulants: past, present and future","volume":"117","author":"Weitz","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.022_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.022_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.022_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ajh.21917","article-title":"Prevalence of clinical venous thromboembolism in the USA: current trends and future projections","volume":"86","author":"Deitelzweig","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.04.022_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.04.022_bib13","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1161\/CIRCULATIONAHA.117.031457","article-title":"Periprocedural outcomes of direct oral anticoagulants versus warfarin in nonvalvular atrial fibrillation","volume":"138","author":"Nazha","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.04.022_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1161\/CIRCULATIONAHA.114.013267","article-title":"Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis","volume":"132","author":"Sharma","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.04.022_bib15","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/bcp.13299","article-title":"Trends in the prescription of novel oral anticoagulants in UK primary care","volume":"83","author":"Loo","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.04.022_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2024.04.022_bib17","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet\u00a0alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.022_bib18","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.022_bib19","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.022_bib20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bjh.15705","article-title":"Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding","volume":"184","author":"Arachchillage","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.04.022_bib22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.022_bib23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","article-title":"Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial","volume":"385","author":"Goldstein","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.04.022_bib24","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.04.022_bib25","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.3324\/haematol.2017.174037","article-title":"Catalytically inactive Gla-domainless factor Xa binds to TFPI and restores ex\u00a0vivo coagulation in hemophilia plasma","volume":"102","author":"Ersayin","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.04.022_bib26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3324\/haematol.2011.055699","article-title":"Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex","volume":"97","author":"Marlu","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.04.022_bib27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1055\/s-0040-1709134","article-title":"Reversal agents for the direct factor Xa inhibitors: biochemical mechanisms of current and newly emerging therapies","volume":"46","author":"Schreuder","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A\u00a0specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.04.022_bib29","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/jth.14487","article-title":"Blood coagulation factor Va's key interactive residues and regions for prothrombinase assembly and prothrombin binding","volume":"17","author":"Schreuder","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/35038119","article-title":"Structure of a serpin-protease complex shows inhibition by deformation","volume":"407","author":"Huntington","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2024.04.022_bib31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1055\/s-0038-1667014","article-title":"FXa-alpha2-macroglobulin complex neutralizes direct oral anticoagulants targeting FXa in\u00a0vitro and in\u00a0vivo","volume":"118","author":"Jourdi","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijbiomac.2021.06.058","article-title":"Induced forms of alpha(2)-macroglobulin neutralize heparin and direct oral anticoagulant effects","volume":"184","author":"Jourdi","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.jtha.2024.04.022_bib33","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nm.4149","article-title":"A\u00a0rapid pro-hemostatic approach to overcome direct oral anticoagulants","volume":"22","author":"Thalji","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.04.022_bib34","doi-asserted-by":"crossref","first-page":"18627","DOI":"10.1074\/jbc.M802205200","article-title":"The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly","volume":"283","author":"Toso","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41467-017-00647-9","article-title":"Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors","volume":"8","author":"Verhoef","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2024.04.022_bib36","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1016\/S0021-9258(18)32440-2","article-title":"The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles","volume":"258","author":"Higgins","year":"1983","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib37","doi-asserted-by":"crossref","first-page":"21643","DOI":"10.1074\/jbc.M402107200","article-title":"Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized","volume":"279","author":"Toso","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib38","doi-asserted-by":"crossref","first-page":"14322","DOI":"10.1021\/bi001074q","article-title":"Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide","volume":"39","author":"Camire","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2024.04.022_bib39","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1021\/bi9623993","article-title":"Contribution of the prothrombin fragment 2 domain to the function of factor Va in the prothrombinase complex","volume":"36","author":"Krishnaswamy","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2024.04.022_bib40","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2009-02-202663","article-title":"Venom factor V from the common brown snake escapes hemostatic regulation through procoagulant adaptations","volume":"114","author":"Bos","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.022_bib41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1160\/th15-04-0354","article-title":"Role of exosite binding modulators in the inhibition of Fxa by TFPI","volume":"115","author":"Peraramelli","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib42","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The Amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"J\u00a0Comput Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib43","series-title":"AMBER 2020","author":"Case","year":"2020"},{"key":"10.1016\/j.jtha.2024.04.022_bib44","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J\u00a0Chem Theory Comput"},{"key":"10.1016\/j.jtha.2024.04.022_bib45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.jtha.2024.04.022_bib46","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA.py: an efficient program for end-state free energy calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J\u00a0Chem Theory Comput"},{"key":"10.1016\/j.jtha.2024.04.022_bib47","doi-asserted-by":"crossref","first-page":"16621","DOI":"10.1074\/jbc.271.28.16621","article-title":"Kinetics of blood coagulation factor Xa alpha autoproteolytic conversion to factor Xabeta. Effect on inhibition by antithrombin, prothrombinase assembly, and enzyme activity","volume":"271","author":"Pryzdial","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib48","series-title":"Williams Hematology","first-page":"2017","article-title":"Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis","author":"Bos","year":"2021"},{"key":"10.1016\/j.jtha.2024.04.022_bib49","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib50","doi-asserted-by":"crossref","first-page":"17241","DOI":"10.1074\/jbc.M312827200","article-title":"Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III","volume":"279","author":"Lu","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib51","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1016\/S0021-9258(19)70686-3","article-title":"Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor","volume":"255","author":"Zur","year":"1980","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib52","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2024.04.022_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2024.04.022_bib54","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2024.04.022_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-023-01837-0","article-title":"Evolving trends in consumption of direct oral anticoagulants in 65 countries\/regions from 2008 to 2019","volume":"83","author":"Yan","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2024.04.022_bib56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: a 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Comput Sci Eng"},{"key":"10.1016\/j.jtha.2024.04.022_bib57","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.1074\/jbc.272.35.21713","article-title":"Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors","volume":"272","author":"Renatus","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib58","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1160\/TH04-06-0384","article-title":"Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin","volume":"92","author":"Olson","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib59","doi-asserted-by":"crossref","first-page":"37863","DOI":"10.1074\/jbc.M203692200","article-title":"Prothrombinase assembly and S1 site occupation restore the catalytic activity of FXa impaired by mutation at the sodium-binding site","volume":"277","author":"Camire","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.04.022_bib60","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nsmb811","article-title":"Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin","volume":"11","author":"Li","year":"2004","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jtha.2024.04.022_bib61","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/sj.emboj.7601089","article-title":"Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation","volume":"25","author":"Johnson","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.jtha.2024.04.022_bib62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/jth.15547","article-title":"The preAR2 region (1458-1492) in factor V-short is crucial for the synergistic TFPI\u03b1-cofactor activity with protein S and the assembly of a trimolecular factor Xa-inhibitory complex comprising FV-Short, protein S, and TFPI\u03b1","volume":"20","author":"Dahlback","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib63","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2141.2008.07267.x","article-title":"Thrombin generation testing in routine clinical practice: are we there yet?","volume":"142","author":"van Veen","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.04.022_bib64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0268-960X(94)90007-8","article-title":"Biochemistry of factor X","volume":"8","author":"Hertzberg","year":"1994","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.04.022_bib65","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.022_bib66","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.022_bib67","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"Waters","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.04.022_bib68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2741\/3926","article-title":"Tissue factor pathway inhibitor: structure-function","volume":"17","author":"Broze","year":"2012","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.jtha.2024.04.022_bib69","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood-2013-11-512764","article-title":"Biology of tissue factor pathway inhibitor","volume":"123","author":"Wood","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.022_bib70","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/cbdd.13568","article-title":"An unexpected dynamic binding mode between coagulation factor X and rivaroxaban reveals importance of flexibility in drug binding","volume":"94","author":"Qu","year":"2019","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.jtha.2024.04.022_bib71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1538-7836.2004.01021.x","article-title":"Exosite-driven substrate specificity and function in coagulation","volume":"3","author":"Krishnaswamy","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib72","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1055\/s-0040-1715441","article-title":"Evolutionary adaptations in Pseudonaja textilis venom factor X induce zymogen activity and resistance to the intrinsic tenase complex","volume":"120","author":"Schreuder","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib73","article-title":"Andexanet\u00a0alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model","volume":"13","author":"Lu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.04.022_bib74","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/bloodadvances.2020001699","article-title":"An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms","volume":"4","author":"von Drygalski","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.04.022_bib75","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.thromres.2020.11.023","article-title":"Elevated anti-human factor Xa activity in rabbit and rodent plasma: implications for preclinical assessment of human factor X in animal models of hemostasis","volume":"198","author":"Verhoef","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.04.022_bib76","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1538-7836.2009.03454.x","article-title":"Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice","volume":"7","author":"Maroney","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.022_bib77","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet\u00a0alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.04.022_bib78","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1055\/s-0029-1225763","article-title":"Factor X deficiency","volume":"35","author":"Menegatti","year":"2009","journal-title":"Semin Thromb Hemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400254X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400254X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T22:06:10Z","timestamp":1721685970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362400254X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S153878362400254X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.04.022","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}